stockportfolio.pro
Certara, Inc. (CERT)
Healthcare · Health Information Services · NasdaqGS
Certara, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $208.51M | $243.53M | $286.10M | $335.64M | $354.34M | $385.15M | $418.84M |
| Gross profit | $128.74M | $142.76M | $174.49M | $203.07M | $213.31M | — | — |
| Net income | $-8.93M | $-49.40M | $-13.27M | $14.73M | $-55.36M | $-12.05M | $-1.59M |
| Net margin | -4.3% | -20.3% | -4.6% | 4.4% | -15.6% | -3.1% | -0.4% |
Source: Certara, Inc. SEC filings (10-K).
Explore 7 years of Certara, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CERT in your portfolio →
About Certara, Inc.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Certara, Inc. — frequently asked questions
What is Certara, Inc.'s revenue?
Certara, Inc. (CERT) reported revenue of $418.84M for fiscal year 2025, up 8.7% from the prior year, according to its SEC filings.
Is Certara, Inc. profitable?
No — CERT reported a net loss of $-1.59M in fiscal 2025.
What is CERT's P/E ratio?
Certara, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Certara, Inc. growing?
CERT's revenue grew at roughly 11.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Certara, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.